CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
Serplulimab and Chemotherapydrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05775796
NCT05775796Phase 2Completed
CompareCT.gov

A Single-arm, Multicenter, and Phase II Clinical Study to Evaluate the Efficacy and Safety of Serplulimab Combined With Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable Stage II-IIIA NSCLC

Fudan University·interventional·Posted Mar 20, 2023·Updated Oct 1, 2025

In Brief

A Phase 2 clinical trial evaluating Serplulimab and Chemotherapy for Non-small Cell Lung Cancer and 3 related conditions. Completed, enrolled 30 participants across 1 site.

Detailed Summary

This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1013. The purpose of this neoadjuvant and adjuvant study is to evaluate the efficacy and safety of Serplulimab and chemotherapy in treating resectable Non-Small Cell Lung Cancer(NSCLC). The study also intended to explore the immune function of tumor-draining lymph nodes during immunotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer, Stage II-IIIA, Immunotherapy, Neoadjuvant Therapy
CountriesChina
Collaborators--

Timeline

Phase 2CompletedFinished
202420252026
First PostedMar 20, 2023
Enrollment StartMar 15, 2023
Primary CompletionMay 28, 2024
Study CompletionSep 1, 2025
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 3.3 years ago

Interventions

Serplulimab and Chemotherapydrug

Serplulimab+Paclitaxel+Cisplatin/Carboplatin Serplulimab+Pemetrexed+Cisplatin/Carboplatin